When coverage decisions are based on the “average patient,” patient diversity, heterogeneous treatment effects, and heterogeneous preferences are frequently ignored. Yet historically, value assessment models have been based on this concept of the average patient. As an alternative to cost-effectiveness analysis, multi-criteria decision (MCDA) can offer additional insight by accounting for patient preferences related to attributes not easily included in cost-effectiveness approaches. This project explores the influence of patient preferences on conclusions about relative value of treatments for non-small cell lung cancer (NSCLC) using the MCDA capabilities of the IVI-NSCLC model.

Working with clinical experts, researchers will develop prototypes of patients with a diversity of preferences, and then use the IVI-NSCLC Value Model to see how these patients respond to typical types of treatment sequences. From this we can determine whether preferred treatment regimens differ between patients with different preferences.

IVI is currently interviewing clinical experts and developing preferences profiles for example patients. Analysis is expected to be completed in February 2020, with results available in March 2020.